
Liquidia (LQDA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
3.1M
Gross Profit
1.6M
51.38%
Operating Income
-35.4M
-1,135.42%
Net Income
-38.4M
-1,229.71%
EPS (Diluted)
$-0.45
Balance Sheet Metrics
Total Assets
227.4M
Total Liabilities
177.7M
Shareholders Equity
49.7M
Debt to Equity
3.57
Cash Flow Metrics
Operating Cash Flow
-26.7M
Free Cash Flow
-31.0M
Revenue & Profitability Trend
Liquidia Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 14.0M | 17.5M | 15.9M | 12.9M | 739.6K |
Cost of Goods Sold | 5.9M | 2.9M | 2.9M | 3.0M | 237.7K |
Gross Profit | 8.1M | 14.6M | 13.1M | 9.8M | 501.9K |
Gross Margin % | 58.0% | 83.5% | 82.1% | 76.5% | 67.9% |
Operating Expenses | |||||
Research & Development | 47.8M | 43.2M | 19.4M | 20.5M | 32.2M |
Selling, General & Administrative | 81.6M | 44.7M | 32.4M | 23.1M | 27.4M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 129.4M | 88.0M | 51.8M | 43.6M | 59.6M |
Operating Income | -121.3M | -73.4M | -38.8M | -33.8M | -59.1M |
Operating Margin % | -866.6% | -419.6% | -243.3% | -263.0% | -7,989.0% |
Non-Operating Items | |||||
Interest Income | 7.7M | 3.5M | 1.1M | 33.0K | 184.4K |
Interest Expense | 12.5M | 6.3M | 2.3M | 762.0K | 858.0K |
Other Non-Operating Income | -4.3M | -2.3M | -997.0K | -53.0K | - |
Pre-tax Income | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M |
Income Tax | - | - | - | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M |
Net Margin % | -931.7% | -448.9% | -257.4% | -269.0% | -8,080.1% |
Key Metrics | |||||
EBITDA | -111.4M | -67.7M | -34.0M | -28.2M | -55.8M |
EPS (Basic) | $-1.66 | $-1.21 | $-0.67 | $-0.70 | $-1.76 |
EPS (Diluted) | $-1.66 | $-1.21 | $-0.67 | $-0.70 | $-1.76 |
Basic Shares Outstanding | 78707503 | 64993476 | 60958862 | 49677737 | 33888434 |
Diluted Shares Outstanding | 78707503 | 64993476 | 60958862 | 49677737 | 33888434 |
Income Statement Trend
Liquidia Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 176.5M | 83.7M | 93.3M | 57.5M | 65.3M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 2.7M | 4.1M | 5.0M | 3.0M | 0 |
Inventory | 241.0K | - | - | - | - |
Other Current Assets | 5.7M | 2.2M | 1.5M | 792.0K | 752.4K |
Total Current Assets | 185.1M | 89.9M | 99.8M | 61.3M | 66.1M |
Non-Current Assets | |||||
Property, Plant & Equipment | 11.1M | 8.5M | 8.4M | 9.0M | 10.1M |
Goodwill | 11.0M | 11.2M | 11.5M | 12.2M | 13.3M |
Intangible Assets | 3.2M | 3.4M | 3.7M | 4.4M | 5.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 25.7M | 14.9M | 15.5M | 16.7M | 13.2M |
Total Non-Current Assets | 45.2M | 28.4M | 29.4M | 32.5M | 33.5M |
Total Assets | 230.3M | 118.3M | 129.2M | 93.7M | 99.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.7M | 1.4M | 2.2M | 1.1M | 3.7M |
Short-term Debt | 18.4M | 1.1M | 1.1M | 1.1M | 1.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | 1.8M |
Total Current Liabilities | 41.8M | 18.6M | 8.8M | 7.3M | 11.7M |
Non-Current Liabilities | |||||
Long-term Debt | 104.0M | 2.4M | 23.4M | 15.0M | 15.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 111.3M | 52.5M | 30.0M | 21.1M | 16.7M |
Total Liabilities | 153.0M | 71.0M | 38.8M | 28.5M | 28.4M |
Equity | |||||
Common Stock | 85.0K | 69.0K | 64.0K | 52.0K | 43.3K |
Retained Earnings | -559.5M | -429.1M | -350.6M | -309.6M | -275.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 77.3M | 47.3M | 90.4M | 65.3M | 71.1M |
Key Metrics | |||||
Total Debt | 122.4M | 3.5M | 24.5M | 16.1M | 17.1M |
Working Capital | 143.3M | 71.3M | 91.0M | 53.9M | 54.3M |
Balance Sheet Composition
Liquidia Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -130.4M | -78.5M | -41.0M | -34.6M | -59.8M |
Depreciation & Amortization | 2.2M | 2.2M | 3.6M | 5.6M | 3.1M |
Stock-Based Compensation | 18.8M | 10.1M | 9.3M | 6.7M | 4.0M |
Working Capital Changes | -8.2M | -1.1M | -2.0M | -13.0M | -1.8M |
Operating Cash Flow | -101.1M | -50.8M | -29.4M | -34.8M | -54.2M |
Investing Activities | |||||
Capital Expenditures | -4.9M | -1.3M | -587.0K | -107.0K | -752.1K |
Acquisitions | - | - | - | 0 | 1.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -4.9M | -1.3M | -587.0K | -107.0K | 247.9K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 57.5M | 41.7M | 19.8M | 10.4M | 0 |
Debt Repayment | -5.0M | -22.4M | -10.8M | -10.8M | -6.8M |
Financing Cash Flow | 191.6M | 42.1M | 63.9M | 26.3M | 63.3M |
Free Cash Flow | -101.9M | -52.9M | -29.2M | -34.1M | -54.9M |
Net Change in Cash | 85.6M | -10.0M | 33.9M | -8.6M | 9.4M |
Cash Flow Trend
Liquidia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-16.17
Forward P/E
-17.21
Price to Book
151.64
Price to Sales
119.59
PEG Ratio
-0.50
Profitability Ratios
Profit Margin
58.00%
Operating Margin
-424.41%
Return on Equity
-389.13%
Return on Assets
-39.74%
Financial Health
Current Ratio
2.49
Debt to Equity
1,319.26
Beta
0.15
Per Share Data
EPS (TTM)
$-1.82
Book Value per Share
$0.18
Revenue per Share
$0.23
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
lqda | 2.3B | -16.17 | 151.64 | -389.13% | 58.00% | 1,319.26 |
Vertex | 101.3B | 28.08 | 5.90 | 22.77% | 31.86% | 8.89 |
Regeneron | 63.6B | 15.12 | 2.09 | 15.34% | 31.37% | 9.04 |
BridgeBio Pharma | 9.6B | -17.12 | -5.28 | 36.76% | 98.25% | -1.04 |
Madrigal | 9.1B | -18.94 | 13.00 | -36.30% | -54.68% | 17.81 |
Halozyme | 8.4B | 16.39 | 25.31 | 179.14% | 47.28% | 462.23 |
Financial data is updated regularly. All figures are in the company's reporting currency.